GSK signs £50m deal with Oxford University on cancer vaccines
GuardianFEB 2
GSK, Oxford Launch $62M Cancer Prevention Vaccine Program
Above: British Prime Minister Sir Keir Starmer (R) in conversation with former CEO of Google, Eric Schmdit (C), and the CEO of GSK, Dame Emma Walmsley (L) during the International Investment Summit on Oct. 14, 2024, in London, England. Image copyright: Jonathan Brady/WPA Pool/Getty Images News via Getty Images
The Spin
Narrative A
Cancer vaccines could revolutionize the fight against one of the world's top killers, with the UK leading the charge. These vaccines are tailored to individual tumors, targeting specific cancer cell antigens not found on healthy cells. This precision would reduce side effects and boost efficacy. This program puts the nation at the forefront of this promising field, potentially turning cancer from a death sentence into a manageable condition.
Narrative B
While it's easy to support seemingly altruistic promises to cure cancer, the pharmaceutical and technology corporations behind these endeavors must be viewed with guarded optimism. For example, Oracle owner Larry Ellison has promised to create vaccines in just 48 hours just by using AI — an overly ambitious promise that clearly prioritizes quantity over quality. Given the industry's complicated history, it's essential to critically evaluate these innovations rather than accept them at face value.